Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited

Navigating SG&A Expenses: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, effective cost management is crucial for maintaining competitive advantage. Over the past decade, Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead Sciences saw a significant increase of approximately 104% in SG&A expenses, peaking at $6.09 billion in 2023. This upward trajectory reflects Gilead's strategic investments in marketing and administrative capabilities to support its expanding portfolio.

Conversely, Teva Pharmaceutical experienced a 31% decline in SG&A expenses, dropping to $3.50 billion in 2023. This reduction highlights Teva's focus on cost optimization amidst challenging market conditions. The contrasting strategies of these two industry leaders underscore the diverse approaches to cost management in the pharmaceutical sector, offering valuable insights for stakeholders and investors alike.